Patents by Inventor James D. Marks

James D. Marks has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Internalizing human monoclonal antibodies targeting prostate cancer cells in situ
    Patent number: 9593162
    Abstract: This invention provides a method that allows selection of antibodies against cells (e.g., tumor cells) in situ using laser capture microdissection. By restricting antibody selection to binders of internalizing epitopes, a panel of phage antibodies was generated that targets clinically represented prostate cancer antigens.
    Type: Grant
    Filed: September 15, 2014
    Date of Patent: March 14, 2017
    Assignee: The Regents of the University of California
    Inventors: Bin Liu, James D. Marks
  • ANTI-EPHA2 ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20160376369
    Abstract: Antibodies that bind to tumor associated antigen CD44 or to tumor associated antigen EphA2, are disclosed herein, as well as related compositions and methods of use. Methods of use encompass cancer therapies, diagnostics, and screening methods.
    Type: Application
    Filed: August 9, 2016
    Publication date: December 29, 2016
    Inventors: Yu Zhou, James D. Marks
  • High affinity anti-prostate stem cell antigen (PSCA) antibodies for cancer targeting and detection
    Patent number: 9527919
    Abstract: The present invention provides novel high affinity antibodies and fragments thereof that bind to the cancer antigen PSCA. The antibodies of the present invention may be used for cancer diagnosis, prognosis, treatment, visualization, and the like. The Present invention also provides methods for the detection, visualization, and treatment of various cancers expressing PSCA.
    Type: Grant
    Filed: December 5, 2014
    Date of Patent: December 27, 2016
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Anna M. Wu, Robert E. Reiter, Eric J. Lepin, James D. Marks, Yu Zhou
  • Internalizing ErbB2 Antibodies
    Publication number: 20160279262
    Abstract: This invention provides novel erbB2-binding internalizing antibodies. The antibodies, designated F5 and C1, specifically bind to c-erbB2 antigen and, upon binding, are readily internalizing into the cell bearing the c-erbB2 marker. Chimeric molecules comprising the F5 and/or C1 antibodies attached to one or more effector molecules are also provided.
    Type: Application
    Filed: June 9, 2016
    Publication date: September 29, 2016
    Inventors: James D. Marks, Marie Alix Poul
  • Antibodies that neutralize botulinum neurotoxins
    Patent number: 9453068
    Abstract: This disclosure provides antibodies that specifically bind to and typically neutralize botulinum neurotoxins (e.g., BoNT/A, BoNT/B, BoNT/E, etc.) and the epitopes bound by those antibodies. The antibodies and derivatives thereof and/or other antibodies that specifically bind to the neutralizing epitopes provided herein can be used to neutralize botulinum neurotoxin and are therefore also useful in the treatment of botulism.
    Type: Grant
    Filed: February 27, 2015
    Date of Patent: September 27, 2016
    Assignee: The Regents of the University of California
    Inventors: James D. Marks, Jianlong Lou
  • Anti-EphA2 antibodies and methods of use thereof
    Patent number: 9446125
    Abstract: Antibodies that bind to tumor associated antigen CD44 or to tumor associated antigen EphA2, are disclosed herein, as well as related compositions and methods of use. Methods of use encompass cancer therapies, diagnostics, and screening methods.
    Type: Grant
    Filed: August 18, 2015
    Date of Patent: September 20, 2016
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, BERKE
    Inventors: Yu Zhou, James D. Marks
  • Antibodies for Botulinum Neurotoxins
    Publication number: 20160229921
    Abstract: The present disclosure provides antibodies that specifically bind to botulinum neurotoxins (e.g., BoNT/A, BoNT/B, BoNT/C, BoNT/D, BoNT/E, BoNT/F, BoNT/G, etc.) and the epitopes bound by those antibodies. The antibodies and derivatives thereof that specifically bind to the neutralizing epitopes provided herein can be used to neutralize botulinum neurotoxin and are therefore also useful in the treatment of botulism.
    Type: Application
    Filed: December 11, 2015
    Publication date: August 11, 2016
    Inventors: James D. Marks, Yongfeng Fan, Jianlong Lou, Maria Consuelo Garcia Rodriguez, Shude Yan, Isin Nergiz Geren, Wenwu Zhai, Subhendu Chakraborti
  • Therapeutic Monoclonal Antibodies that Neutralize Botulinum Neurotoxins
    Publication number: 20160168265
    Abstract: This invention provides antibodies that specifically bind to and typically neutralize botulinum neurotoxins (e.g., BoNT/A, BoNT/B, BoNT/E, etc.) and the epitopes bound by those antibodies. The antibodies and derivatives thereof and/or other antibodies that specifically bind to the neutralizing epitopes provided herein can be used to neutralize botulinum neurotoxin and are therefore also useful in the treatment of botulism.
    Type: Application
    Filed: October 1, 2015
    Publication date: June 16, 2016
    Inventors: James D. Marks, Isin N. Geren, Maria Consuelo Garcia, Jianlong Lou, Ali Razai
  • INTEGRIN ALPHA-V BETA8 NEUTRALIZING ANTIBODY
    Publication number: 20160137737
    Abstract: The present invention relates to ?v?8 antagonists, anti-?v?8 antibodies or immunoconjugates for reducing TGF? activation in an individual. Further provided are compositions comprising one of the ?v?8 antagonists, anti-?v?8 antibodies or immunoconjugates, methods for using the compositions, and related subject matter.
    Type: Application
    Filed: January 21, 2016
    Publication date: May 19, 2016
    Inventors: Stephen Nishimura, Jianlong Lou, Jody Lynn Baron, James D. Marks
  • GLIOBLASTOMA MULTIFORME-REACTIVE ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20160096883
    Abstract: The present disclosure is generally related to antibodies that bind specifically to glioblastoma multiforme (GBM) cells. In particular, the present disclosure provides compositions comprising human single chain or full-length antibodies that bind tumor cells. Additionally the present disclosure provides methods of using the anti-GBM antibodies.
    Type: Application
    Filed: August 26, 2015
    Publication date: April 7, 2016
    Inventors: Bin LIU, James D. MARKS, Xiaodong ZHU, Scott BIDLINGMAIER
  • Integrin ?-V?8 neutralizing antibody
    Patent number: 9290572
    Abstract: The present invention relates to ?v?8 antagonists, anti-?v?8 antibodies or immunoconjugates for reducing TGF? activation in an individual. Further provided are compositions comprising one of the ?v?8 antagonists, anti-?v?8 antibodies or immunoconjugates, methods for using the compositions, and related subject matter.
    Type: Grant
    Filed: February 18, 2011
    Date of Patent: March 22, 2016
    Assignee: The Regents of the University of California
    Inventors: Stephen Nishimura, Jianlong Lou, Jody Lynn Baron, James D. Marks
  • Antibodies for botulinum neurotoxins
    Patent number: 9243057
    Abstract: The present disclosure provides antibodies that specifically bind to botulinum neurotoxins (e.g., BoNT/A, BoNT/B, BoNT/C, BoNT/D, BoNT/E, BoNT/F, BoNT/G, etc.) and the epitopes bound by those antibodies. The antibodies and derivatives thereof that specifically bind to the neutralizing epitopes provided herein can be used to neutralize botulinum neurotoxin and are therefore also useful in the treatment of botulism.
    Type: Grant
    Filed: August 31, 2011
    Date of Patent: January 26, 2016
    Assignee: The Regents of the University of California
    Inventors: James D. Marks, Maria Consuelo Garcia Rodriguez
  • ANTI-CD83 ANTIBODIES AND USE THEREOF
    Publication number: 20150376277
    Abstract: The present disclosure relates to proteins that bind to CD83 and uses thereof, for example, in therapy, prophylaxis, diagnosis, or prognosis.
    Type: Application
    Filed: January 31, 2014
    Publication date: December 31, 2015
    Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Therese Ann Seldon, David John Munster, Derek Nigel John Hart, Martina Louise Jones, Trent Phillip Munro, Stephen Michael Mahler, Eunice Yu Zhou, James D. Marks
  • Anti-tumor antigen antibodies and methods of use
    Patent number: 9220772
    Abstract: Antibodies that bind to tumor associated antigen CD44 or to tumor associated antigen EphA2, are disclosed herein, as well as related compositions and methods of use. Methods of use encompass cancer therapies, diagnostics, and screening methods.
    Type: Grant
    Filed: July 22, 2011
    Date of Patent: December 29, 2015
    Assignee: The Regents of the University of California
    Inventors: Yu Zhou, James D. Marks
  • ANTI-EPHA2 ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20150343081
    Abstract: Antibodies that bind to tumor associated antigen CD44 or to tumor associated antigen EphA2, are disclosed herein, as well as related compositions and methods of use. Methods of use encompass cancer therapies, diagnostics, and screening methods.
    Type: Application
    Filed: August 18, 2015
    Publication date: December 3, 2015
    Inventors: Yu Zhou, James D. Marks
  • Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
    Patent number: 9181330
    Abstract: This invention provides antibodies that specifically bind to and typically neutralize botulinum neurotoxins (e.g., BoNT/A, BoNT/B, BoNT/E, etc.) and the epitopes bound by those antibodies. The antibodies and derivatives thereof and/or other antibodies that specifically bind to the neutralizing epitopes provided herein can be used to neutralize botulinum neurotoxin and are therefore also useful in the treatment of botulism.
    Type: Grant
    Filed: September 24, 2013
    Date of Patent: November 10, 2015
    Assignee: The Regents of the University of California
    Inventors: James D. Marks, Maria Consuelo Garcia
  • Glioblastoma multiforme-reactive antibodies and methods of use thereof
    Patent number: 9145462
    Abstract: The present disclosure is generally related to antibodies that bind specifically to glioblastoma multiforme (GBM) cells. In particular, the present disclosure provides compositions comprising human single chain or full-length antibodies that bind tumor cells. Additionally the present disclosure provides methods of using the anti-GBM antibodies.
    Type: Grant
    Filed: June 29, 2011
    Date of Patent: September 29, 2015
    Assignee: The Regents of the University of California
    Inventors: Bin Liu, James D. Marks, Xiaodong Zhu, Scott Bidlingmaier
  • HIGH AFFINITY ANTI-PROSTATE STEM CELL ANTIGEN (PSCA) ANTIBODIES FOR CANCER TARGETING AND DETECTION
    Publication number: 20150239983
    Abstract: The present invention provides novel high affinity antibodies and fragments thereof that bind to the cancer antigen PSCA. The antibodies of the present invention may be used for cancer diagnosis, prognosis, treatment, visualization, and the like. The Present invention also provides methods for the detection, visualization, and treatment of various cancers expressing PSCA.
    Type: Application
    Filed: December 5, 2014
    Publication date: August 27, 2015
    Inventors: Anna M. WU, Robert E. Reiter, Eric J. Lepin, James D. Marks, Yu Zhou
  • Antibodies that Neutralize Botulinum Neurotoxins
    Publication number: 20150197559
    Abstract: This disclosure provides antibodies that specifically bind to and typically neutralize botulinum neurotoxins (e.g., BoNT/A, BoNT/B, BoNT/E, etc.) and the epitopes bound by those antibodies. The antibodies and derivatives thereof and/or other antibodies that specifically bind to the neutralizing epitopes provided herein can be used to neutralize botulinum neurotoxin and are therefore also useful in the treatment of botulism.
    Type: Application
    Filed: February 27, 2015
    Publication date: July 16, 2015
    Inventors: James D. Marks, Jianlong Lou, Maria Consuelo Garcia Rodriguez, Isin N. Geren
  • Antibodies that neutralize botulinum neurotoxins
    Patent number: 9000131
    Abstract: This disclosure provides antibodies that specifically bind to and typically neutralize botulinum neurotoxins (e.g., BoNT/A, BoNT/B, BoNT/E, etc.) and the epitopes bound by those antibodies. The antibodies and derivatives thereof and/or other antibodies that specifically bind to the neutralizing epitopes provided herein can be used to neutralize botulinum neurotoxin and are therefore also useful in the treatment of botulism.
    Type: Grant
    Filed: July 30, 2009
    Date of Patent: April 7, 2015
    Assignee: The Regents of the University of California
    Inventors: James D. Marks, Isin N. Geren